Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 40 | 2023 | 20059 | 2.650 |
Why?
|
Oxidative Stress | 31 | 2022 | 3163 | 2.600 |
Why?
|
Nitric Oxide | 25 | 2020 | 2121 | 1.570 |
Why?
|
Pesticides | 2 | 2022 | 289 | 1.430 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 2 | 2020 | 235 | 1.370 |
Why?
|
Glutathione Transferase | 2 | 2021 | 616 | 1.370 |
Why?
|
Arachidonate 5-Lipoxygenase | 2 | 2019 | 148 | 1.100 |
Why?
|
Carcinoma, Ductal, Breast | 6 | 2021 | 1102 | 1.050 |
Why?
|
Receptor, erbB-2 | 7 | 2022 | 2331 | 1.020 |
Why?
|
Oxidation-Reduction | 10 | 2022 | 2334 | 0.980 |
Why?
|
Atrazine | 1 | 2022 | 8 | 0.930 |
Why?
|
Chagas Disease | 3 | 2020 | 167 | 0.930 |
Why?
|
Proteomics | 9 | 2019 | 3256 | 0.930 |
Why?
|
Agricultural Workers' Diseases | 1 | 2022 | 34 | 0.900 |
Why?
|
Nitric Oxide Synthase Type II | 8 | 2020 | 560 | 0.900 |
Why?
|
Antioxidants | 9 | 2022 | 1689 | 0.870 |
Why?
|
Leishmania | 5 | 2021 | 64 | 0.850 |
Why?
|
Lipid Peroxidation | 15 | 2022 | 316 | 0.800 |
Why?
|
Antiprotozoal Agents | 5 | 2019 | 91 | 0.790 |
Why?
|
Doxorubicin | 5 | 2021 | 2233 | 0.780 |
Why?
|
Plant Leaves | 1 | 2020 | 137 | 0.780 |
Why?
|
Trypanosoma cruzi | 6 | 2020 | 201 | 0.770 |
Why?
|
Paclitaxel | 5 | 2021 | 1674 | 0.750 |
Why?
|
Brazil | 6 | 2022 | 1149 | 0.690 |
Why?
|
Reactive Oxygen Species | 11 | 2022 | 2148 | 0.680 |
Why?
|
Hospital Records | 1 | 2018 | 95 | 0.670 |
Why?
|
Leishmaniasis, Cutaneous | 4 | 2021 | 117 | 0.620 |
Why?
|
Peroxidase | 1 | 2020 | 624 | 0.600 |
Why?
|
Mass Spectrometry | 5 | 2016 | 2252 | 0.600 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2017 | 631 | 0.600 |
Why?
|
Macrophages, Peritoneal | 5 | 2020 | 275 | 0.590 |
Why?
|
Caffeine | 1 | 2020 | 700 | 0.570 |
Why?
|
Cytokines | 11 | 2019 | 7225 | 0.550 |
Why?
|
Autoimmunity | 2 | 2020 | 1332 | 0.540 |
Why?
|
Pain, Intractable | 1 | 2015 | 129 | 0.540 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 273 | 0.520 |
Why?
|
Mammary Glands, Human | 1 | 2015 | 206 | 0.520 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1785 | 0.490 |
Why?
|
Tumor Microenvironment | 5 | 2023 | 3071 | 0.480 |
Why?
|
Gene Expression Regulation, Neoplastic | 10 | 2023 | 8674 | 0.480 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 511 | 0.460 |
Why?
|
Neoplasms | 8 | 2022 | 20515 | 0.460 |
Why?
|
Propolis | 3 | 2016 | 6 | 0.450 |
Why?
|
Prognosis | 15 | 2023 | 29168 | 0.430 |
Why?
|
Metformin | 4 | 2020 | 803 | 0.420 |
Why?
|
Occupational Exposure | 1 | 2022 | 1775 | 0.420 |
Why?
|
Adiponectin | 2 | 2014 | 1082 | 0.400 |
Why?
|
Proteome | 3 | 2015 | 1770 | 0.380 |
Why?
|
Down-Regulation | 3 | 2020 | 3091 | 0.380 |
Why?
|
Chagas Cardiomyopathy | 1 | 2010 | 73 | 0.380 |
Why?
|
Concanavalin A | 2 | 2020 | 222 | 0.380 |
Why?
|
Transforming Growth Factor beta | 3 | 2015 | 1996 | 0.360 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2020 | 5238 | 0.360 |
Why?
|
Models, Cardiovascular | 1 | 2014 | 1004 | 0.360 |
Why?
|
Lipid Metabolism | 2 | 2017 | 2003 | 0.350 |
Why?
|
Leukotrienes | 1 | 2010 | 262 | 0.350 |
Why?
|
Female | 61 | 2023 | 377334 | 0.350 |
Why?
|
Leishmania braziliensis | 2 | 2019 | 15 | 0.350 |
Why?
|
Protein Carbonylation | 4 | 2015 | 33 | 0.320 |
Why?
|
Central Nervous System Neoplasms | 1 | 2016 | 870 | 0.320 |
Why?
|
Leishmaniasis | 2 | 2017 | 59 | 0.320 |
Why?
|
Transforming Growth Factor beta1 | 4 | 2020 | 653 | 0.320 |
Why?
|
Anti-Inflammatory Agents | 2 | 2016 | 1797 | 0.320 |
Why?
|
Glutathione | 4 | 2021 | 616 | 0.310 |
Why?
|
Neutrophils | 1 | 2020 | 3850 | 0.310 |
Why?
|
Breast | 1 | 2015 | 1820 | 0.310 |
Why?
|
Chromatography, Liquid | 3 | 2015 | 962 | 0.300 |
Why?
|
Protein Processing, Post-Translational | 1 | 2014 | 2043 | 0.290 |
Why?
|
Lipid Peroxides | 3 | 2022 | 65 | 0.290 |
Why?
|
Humans | 67 | 2023 | 715124 | 0.290 |
Why?
|
DNA Damage | 3 | 2017 | 2467 | 0.280 |
Why?
|
Antineoplastic Agents | 7 | 2022 | 13732 | 0.280 |
Why?
|
Ruthenium Compounds | 2 | 2016 | 8 | 0.270 |
Why?
|
Malondialdehyde | 5 | 2015 | 119 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 8925 | 0.260 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 17395 | 0.260 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4737 | 0.260 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 3970 | 0.260 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2015 | 3010 | 0.260 |
Why?
|
Hematocrit | 1 | 2005 | 638 | 0.250 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2019 | 680 | 0.240 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3777 | 0.240 |
Why?
|
Erythrocytes | 5 | 2015 | 2421 | 0.240 |
Why?
|
Neoplasm Staging | 8 | 2023 | 11192 | 0.240 |
Why?
|
Wedelia | 1 | 2022 | 1 | 0.240 |
Why?
|
Aldrin | 1 | 2022 | 2 | 0.240 |
Why?
|
Trifluralin | 1 | 2022 | 2 | 0.240 |
Why?
|
Diuron | 1 | 2022 | 4 | 0.240 |
Why?
|
Chlordan | 1 | 2022 | 5 | 0.240 |
Why?
|
Arthritis, Gouty | 1 | 2022 | 30 | 0.240 |
Why?
|
Dieldrin | 1 | 2022 | 8 | 0.240 |
Why?
|
Cell Line, Tumor | 11 | 2023 | 16943 | 0.230 |
Why?
|
Middle Aged | 33 | 2022 | 214871 | 0.230 |
Why?
|
DDT | 1 | 2022 | 33 | 0.230 |
Why?
|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2022 | 74 | 0.230 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 3460 | 0.230 |
Why?
|
Rats, Wistar | 8 | 2022 | 2020 | 0.230 |
Why?
|
Dichlorodiphenyl Dichloroethylene | 1 | 2022 | 89 | 0.220 |
Why?
|
Mice, Inbred BALB C | 11 | 2021 | 6677 | 0.220 |
Why?
|
Chalcone | 1 | 2020 | 9 | 0.210 |
Why?
|
Signal Transduction | 11 | 2019 | 23973 | 0.210 |
Why?
|
Chalcones | 1 | 2020 | 28 | 0.200 |
Why?
|
Animals | 33 | 2022 | 170726 | 0.200 |
Why?
|
Leukocytes, Mononuclear | 2 | 2018 | 1734 | 0.200 |
Why?
|
Medulla Oblongata | 1 | 2022 | 248 | 0.200 |
Why?
|
Cell Proliferation | 8 | 2022 | 10800 | 0.200 |
Why?
|
Glutathione S-Transferase pi | 1 | 2020 | 94 | 0.200 |
Why?
|
Halogenation | 1 | 2020 | 47 | 0.190 |
Why?
|
DNA Modification Methylases | 1 | 2021 | 204 | 0.190 |
Why?
|
Inflammation | 9 | 2021 | 10082 | 0.190 |
Why?
|
Inflammation Mediators | 4 | 2021 | 1949 | 0.190 |
Why?
|
Carcinoma | 1 | 2011 | 2325 | 0.190 |
Why?
|
Stress, Psychological | 1 | 2015 | 4168 | 0.190 |
Why?
|
Diterpenes | 2 | 2022 | 180 | 0.190 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2022 | 2085 | 0.180 |
Why?
|
Hypertension | 5 | 2022 | 8247 | 0.180 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 172 | 0.180 |
Why?
|
Obesity | 4 | 2017 | 12192 | 0.180 |
Why?
|
Triclosan | 1 | 2019 | 47 | 0.180 |
Why?
|
Adult | 28 | 2022 | 212129 | 0.180 |
Why?
|
Leishmania mexicana | 2 | 2015 | 32 | 0.180 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 2 | 2016 | 509 | 0.180 |
Why?
|
Quercetin | 1 | 2019 | 91 | 0.180 |
Why?
|
Sodium Glutamate | 3 | 2017 | 27 | 0.180 |
Why?
|
Molecular Targeted Therapy | 4 | 2020 | 2862 | 0.180 |
Why?
|
Ascorbic Acid | 1 | 2022 | 638 | 0.170 |
Why?
|
Aged | 18 | 2022 | 162674 | 0.170 |
Why?
|
Tumor Escape | 1 | 2021 | 339 | 0.170 |
Why?
|
Proteins | 1 | 2014 | 6163 | 0.170 |
Why?
|
Axilla | 1 | 2020 | 540 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2022 | 12567 | 0.170 |
Why?
|
HIV-1 | 2 | 2015 | 6784 | 0.170 |
Why?
|
Monoterpenes | 1 | 2017 | 17 | 0.160 |
Why?
|
1,2-Dimethylhydrazine | 1 | 2016 | 8 | 0.160 |
Why?
|
Superoxide Dismutase | 3 | 2022 | 604 | 0.160 |
Why?
|
Aberrant Crypt Foci | 1 | 2016 | 10 | 0.160 |
Why?
|
Pharmacogenetics | 1 | 2022 | 699 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2018 | 221 | 0.160 |
Why?
|
Silver | 1 | 2017 | 121 | 0.160 |
Why?
|
Anti-Infective Agents, Local | 1 | 2019 | 235 | 0.160 |
Why?
|
Nitroso Compounds | 1 | 2016 | 70 | 0.150 |
Why?
|
Cell Polarity | 1 | 2020 | 653 | 0.150 |
Why?
|
Early Detection of Cancer | 2 | 2021 | 2930 | 0.150 |
Why?
|
Blotting, Western | 2 | 2015 | 5441 | 0.150 |
Why?
|
Paraneoplastic Polyneuropathy | 1 | 2015 | 3 | 0.150 |
Why?
|
Gout | 1 | 2022 | 534 | 0.150 |
Why?
|
Sympathetic Nervous System | 2 | 2022 | 533 | 0.150 |
Why?
|
Trypanocidal Agents | 1 | 2016 | 41 | 0.150 |
Why?
|
Guanidines | 1 | 2017 | 206 | 0.150 |
Why?
|
Nitrates | 2 | 2015 | 261 | 0.150 |
Why?
|
Lupus Erythematosus, Systemic | 3 | 2013 | 2109 | 0.140 |
Why?
|
Liver Neoplasms | 2 | 2022 | 4091 | 0.140 |
Why?
|
Nitroprusside | 1 | 2016 | 286 | 0.140 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3702 | 0.140 |
Why?
|
Fetal Growth Retardation | 1 | 2019 | 556 | 0.140 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 10660 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1055 | 0.140 |
Why?
|
Genes, erbB-2 | 1 | 2015 | 169 | 0.140 |
Why?
|
Apoptosis | 7 | 2022 | 10112 | 0.140 |
Why?
|
Nitric Oxide Donors | 1 | 2015 | 125 | 0.140 |
Why?
|
Uterus | 1 | 2019 | 669 | 0.140 |
Why?
|
Genomics | 2 | 2022 | 5333 | 0.140 |
Why?
|
Interleukin-1beta | 3 | 2015 | 956 | 0.140 |
Why?
|
Monitoring, Immunologic | 1 | 2015 | 105 | 0.140 |
Why?
|
Immunohistochemistry | 6 | 2016 | 11766 | 0.140 |
Why?
|
beta Catenin | 1 | 2020 | 1044 | 0.140 |
Why?
|
Myoblasts, Cardiac | 1 | 2014 | 22 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2015 | 751 | 0.130 |
Why?
|
Catalase | 2 | 2014 | 236 | 0.130 |
Why?
|
Carcinoma, Ductal | 1 | 2015 | 106 | 0.130 |
Why?
|
Brain Neoplasms | 1 | 2016 | 8804 | 0.130 |
Why?
|
Cyclooxygenase 1 | 1 | 2014 | 112 | 0.130 |
Why?
|
Disease Progression | 3 | 2021 | 13302 | 0.130 |
Why?
|
Indomethacin | 1 | 2015 | 353 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2020 | 2970 | 0.130 |
Why?
|
Interleukin-17 | 1 | 2020 | 889 | 0.130 |
Why?
|
Cyclooxygenase 2 | 2 | 2014 | 630 | 0.130 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2015 | 1637 | 0.130 |
Why?
|
Vitamin D | 2 | 2020 | 3163 | 0.130 |
Why?
|
Ferritins | 2 | 2015 | 579 | 0.130 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2016 | 222 | 0.120 |
Why?
|
Melanoma, Experimental | 1 | 2017 | 564 | 0.120 |
Why?
|
Acute Disease | 2 | 2017 | 7177 | 0.120 |
Why?
|
Mice | 16 | 2021 | 80995 | 0.120 |
Why?
|
Albumins | 1 | 2016 | 567 | 0.120 |
Why?
|
Glycerol | 1 | 2014 | 271 | 0.120 |
Why?
|
Statistics, Nonparametric | 3 | 2013 | 2936 | 0.120 |
Why?
|
Enzyme Inhibitors | 4 | 2021 | 3933 | 0.120 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2015 | 637 | 0.120 |
Why?
|
Metal Nanoparticles | 1 | 2017 | 430 | 0.120 |
Why?
|
Maternal Exposure | 1 | 2019 | 906 | 0.110 |
Why?
|
Homocysteine | 1 | 2015 | 659 | 0.110 |
Why?
|
Case-Control Studies | 7 | 2020 | 21790 | 0.110 |
Why?
|
Thiobarbituric Acid Reactive Substances | 1 | 2011 | 53 | 0.110 |
Why?
|
HIV Infections | 2 | 2015 | 15616 | 0.110 |
Why?
|
Oxidants | 1 | 2012 | 166 | 0.110 |
Why?
|
Immunomodulation | 2 | 2016 | 536 | 0.110 |
Why?
|
Drug Therapy | 1 | 2015 | 519 | 0.110 |
Why?
|
Paracoccidioidomycosis | 1 | 2011 | 8 | 0.110 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2019 | 4476 | 0.110 |
Why?
|
Metabolism, Inborn Errors | 1 | 2014 | 291 | 0.110 |
Why?
|
Glycosylation | 1 | 2014 | 1138 | 0.110 |
Why?
|
Tyrosine | 1 | 2016 | 1508 | 0.100 |
Why?
|
Nitrites | 1 | 2011 | 168 | 0.100 |
Why?
|
Area Under Curve | 1 | 2015 | 1693 | 0.100 |
Why?
|
Rats | 9 | 2022 | 25090 | 0.100 |
Why?
|
Rural Population | 1 | 2022 | 2162 | 0.100 |
Why?
|
Iron | 3 | 2019 | 1735 | 0.100 |
Why?
|
Heart Rate | 5 | 2022 | 4102 | 0.100 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2720 | 0.100 |
Why?
|
Metabolic Networks and Pathways | 1 | 2015 | 820 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 15584 | 0.100 |
Why?
|
Skin | 2 | 2016 | 4354 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 11317 | 0.100 |
Why?
|
In Situ Hybridization | 1 | 2014 | 1988 | 0.100 |
Why?
|
Disease-Free Survival | 1 | 2021 | 7051 | 0.100 |
Why?
|
Cardiovascular Diseases | 2 | 2014 | 14326 | 0.100 |
Why?
|
Cell Movement | 2 | 2020 | 5468 | 0.100 |
Why?
|
Mice, Knockout | 2 | 2019 | 15260 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2018 | 3251 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2021 | 3007 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2022 | 3695 | 0.090 |
Why?
|
High-Throughput Screening Assays | 1 | 2014 | 932 | 0.090 |
Why?
|
Male | 25 | 2022 | 351081 | 0.090 |
Why?
|
Th1 Cells | 1 | 2013 | 1080 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2014 | 1415 | 0.080 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2010 | 330 | 0.080 |
Why?
|
Th2 Cells | 1 | 2013 | 1058 | 0.080 |
Why?
|
ROC Curve | 1 | 2015 | 3526 | 0.080 |
Why?
|
Heart Diseases | 1 | 2021 | 2763 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 680 | 0.080 |
Why?
|
Parasitemia | 2 | 2020 | 173 | 0.080 |
Why?
|
Hepatitis C, Chronic | 1 | 2015 | 1003 | 0.080 |
Why?
|
Cell Adhesion | 1 | 2014 | 3311 | 0.080 |
Why?
|
DNA Methylation | 1 | 2021 | 4085 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2019 | 2316 | 0.080 |
Why?
|
Antifungal Agents | 1 | 2011 | 706 | 0.070 |
Why?
|
Immunotherapy | 1 | 2021 | 4118 | 0.070 |
Why?
|
Endotoxemia | 1 | 2007 | 220 | 0.070 |
Why?
|
Homeostasis | 2 | 2015 | 3337 | 0.070 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2011 | 1019 | 0.070 |
Why?
|
Mass Screening | 1 | 2021 | 5204 | 0.070 |
Why?
|
Aspirin | 2 | 2014 | 3166 | 0.070 |
Why?
|
Genotype | 1 | 2020 | 12921 | 0.070 |
Why?
|
Cell Survival | 4 | 2017 | 6131 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 1 | 2018 | 3450 | 0.070 |
Why?
|
Osmotic Pressure | 1 | 2005 | 160 | 0.070 |
Why?
|
Pulmonary Edema | 1 | 2007 | 423 | 0.070 |
Why?
|
Autonomic Nervous System | 2 | 2022 | 674 | 0.060 |
Why?
|
gamma-Glutamyltransferase | 2 | 2015 | 129 | 0.060 |
Why?
|
Nitric Oxide Synthase | 1 | 2007 | 939 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8016 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2237 | 0.060 |
Why?
|
Blood Pressure | 4 | 2022 | 8566 | 0.060 |
Why?
|
Myocardium | 3 | 2017 | 4938 | 0.060 |
Why?
|
Survival Analysis | 2 | 2014 | 10531 | 0.060 |
Why?
|
Cohort Studies | 3 | 2015 | 39804 | 0.060 |
Why?
|
Autophagy | 2 | 2022 | 1345 | 0.060 |
Why?
|
Disabled Persons | 1 | 2012 | 1148 | 0.060 |
Why?
|
Postmenopause | 1 | 2012 | 2420 | 0.060 |
Why?
|
Cell Size | 1 | 2005 | 660 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2015 | 2583 | 0.060 |
Why?
|
Macrophages | 4 | 2021 | 5805 | 0.060 |
Why?
|
Thiohydantoins | 1 | 2022 | 20 | 0.060 |
Why?
|
Fishes | 1 | 2005 | 549 | 0.060 |
Why?
|
Bone Marrow | 1 | 2012 | 2954 | 0.050 |
Why?
|
Computer Simulation | 1 | 2015 | 6075 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2015 | 5125 | 0.050 |
Why?
|
Arginase | 1 | 2021 | 79 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6779 | 0.050 |
Why?
|
Piperazines | 1 | 2012 | 2540 | 0.050 |
Why?
|
Receptors, Estrogen | 3 | 2015 | 2173 | 0.050 |
Why?
|
Dinoprostone | 2 | 2017 | 604 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2014 | 4639 | 0.050 |
Why?
|
Body Mass Index | 2 | 2015 | 12488 | 0.050 |
Why?
|
Histocompatibility Antigens | 1 | 2021 | 526 | 0.050 |
Why?
|
Ganglia, Spinal | 1 | 2022 | 510 | 0.050 |
Why?
|
Heart | 2 | 2010 | 4326 | 0.050 |
Why?
|
Chronic Disease | 1 | 2015 | 9022 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2018 | 5142 | 0.050 |
Why?
|
Pyrimidines | 1 | 2012 | 2969 | 0.050 |
Why?
|
Up-Regulation | 2 | 2020 | 4353 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15258 | 0.050 |
Why?
|
Young Adult | 3 | 2018 | 56155 | 0.050 |
Why?
|
Estrous Cycle | 1 | 2019 | 66 | 0.050 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2021 | 467 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2021 | 469 | 0.050 |
Why?
|
Incidence | 1 | 2018 | 20596 | 0.050 |
Why?
|
Transcription Factor RelA | 1 | 2021 | 294 | 0.050 |
Why?
|
Prospective Studies | 2 | 2014 | 51181 | 0.050 |
Why?
|
Disease Models, Animal | 4 | 2014 | 18345 | 0.050 |
Why?
|
Insulin Resistance | 1 | 2013 | 3890 | 0.040 |
Why?
|
Risk Factors | 3 | 2022 | 70704 | 0.040 |
Why?
|
Cells, Cultured | 4 | 2018 | 20101 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2021 | 588 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5274 | 0.040 |
Why?
|
Anti-HIV Agents | 1 | 2014 | 4040 | 0.040 |
Why?
|
Major Histocompatibility Complex | 1 | 2021 | 1023 | 0.040 |
Why?
|
Leukapheresis | 1 | 2018 | 126 | 0.040 |
Why?
|
NF-kappa B | 2 | 2017 | 2579 | 0.040 |
Why?
|
Acetylation | 1 | 2021 | 1119 | 0.040 |
Why?
|
Liver | 4 | 2015 | 7647 | 0.040 |
Why?
|
Uric Acid | 2 | 2014 | 737 | 0.040 |
Why?
|
Estrogen Receptor alpha | 1 | 2021 | 583 | 0.040 |
Why?
|
Motor Activity | 1 | 2007 | 2755 | 0.040 |
Why?
|
Thyroid Hormones | 1 | 2019 | 377 | 0.040 |
Why?
|
Lactation | 1 | 2019 | 399 | 0.040 |
Why?
|
Phenotype | 1 | 2014 | 16371 | 0.040 |
Why?
|
Nitrosation | 1 | 2016 | 28 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2016 | 6575 | 0.040 |
Why?
|
Phagocytes | 1 | 2018 | 307 | 0.040 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2019 | 335 | 0.040 |
Why?
|
Heme Oxygenase-1 | 1 | 2019 | 385 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2020 | 58505 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9521 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2016 | 2592 | 0.040 |
Why?
|
Mutation | 1 | 2020 | 29442 | 0.030 |
Why?
|
Meglumine | 1 | 2015 | 148 | 0.030 |
Why?
|
Cardiovascular System | 1 | 2022 | 767 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2017 | 700 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 443 | 0.030 |
Why?
|
Cell Membrane | 1 | 2005 | 3912 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2019 | 897 | 0.030 |
Why?
|
Transforming Growth Factor alpha | 1 | 2014 | 138 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2015 | 411 | 0.030 |
Why?
|
Anemia | 2 | 2015 | 1416 | 0.030 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2014 | 249 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2014 | 170 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 22936 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 2015 | 315 | 0.030 |
Why?
|
Fetal Development | 1 | 2019 | 711 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1214 | 0.030 |
Why?
|
Time Factors | 1 | 2015 | 41081 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2016 | 621 | 0.030 |
Why?
|
Hindlimb | 1 | 2015 | 550 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2015 | 599 | 0.030 |
Why?
|
Dinoprost | 1 | 2013 | 146 | 0.030 |
Why?
|
Sulfonamides | 2 | 2014 | 1930 | 0.030 |
Why?
|
Luminescence | 1 | 2012 | 97 | 0.030 |
Why?
|
Mediator Complex | 1 | 2012 | 109 | 0.030 |
Why?
|
Organometallic Compounds | 1 | 2015 | 663 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1573 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2018 | 1694 | 0.030 |
Why?
|
Lung | 3 | 2022 | 9765 | 0.030 |
Why?
|
Pyrazoles | 2 | 2014 | 1974 | 0.030 |
Why?
|
Paracoccidioides | 1 | 2011 | 2 | 0.030 |
Why?
|
C-Reactive Protein | 2 | 2015 | 3707 | 0.030 |
Why?
|
Rodent Diseases | 1 | 2011 | 72 | 0.030 |
Why?
|
X-Rays | 1 | 2011 | 295 | 0.030 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2014 | 720 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2023 | 3503 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1331 | 0.030 |
Why?
|
Phagocytosis | 1 | 2016 | 1588 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 2011 | 331 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1725 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12477 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1878 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13594 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2016 | 3879 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 758 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 23283 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1914 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2022 | 3441 | 0.020 |
Why?
|
Fluorescence | 1 | 2011 | 770 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 6046 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 5098 | 0.020 |
Why?
|
Gene Silencing | 1 | 2015 | 1615 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 2012 | 736 | 0.020 |
Why?
|
Cell Cycle | 1 | 2017 | 3020 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 1408 | 0.020 |
Why?
|
Anthropometry | 1 | 2013 | 1379 | 0.020 |
Why?
|
Hemoglobins | 1 | 2014 | 1501 | 0.020 |
Why?
|
Comorbidity | 1 | 2022 | 10423 | 0.020 |
Why?
|
Blood | 1 | 2010 | 618 | 0.020 |
Why?
|
Models, Statistical | 1 | 2022 | 5028 | 0.020 |
Why?
|
Pain | 1 | 2022 | 4662 | 0.020 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2007 | 173 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 1119 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 3963 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2014 | 39285 | 0.020 |
Why?
|
Swimming | 1 | 2007 | 200 | 0.020 |
Why?
|
Benzamides | 1 | 2012 | 1411 | 0.020 |
Why?
|
Collagen | 1 | 2015 | 2687 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1921 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2021 | 5977 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 3614 | 0.020 |
Why?
|
Vitamin D Deficiency | 1 | 2015 | 1367 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2012 | 1823 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6538 | 0.020 |
Why?
|
Fibroblasts | 1 | 2015 | 4283 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2266 | 0.020 |
Why?
|
Wound Healing | 1 | 2015 | 2797 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2960 | 0.020 |
Why?
|
Hospitalization | 1 | 2022 | 9718 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 7213 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 2480 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2016 | 62186 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2014 | 2950 | 0.010 |
Why?
|
Organ Size | 1 | 2007 | 2313 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 1847 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 11285 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5153 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 13268 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 2268 | 0.010 |
Why?
|
Cell Line | 1 | 2014 | 16680 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 13255 | 0.010 |
Why?
|
Public Health | 1 | 2011 | 2374 | 0.010 |
Why?
|
Blood Glucose | 1 | 2013 | 6293 | 0.010 |
Why?
|
Sex Factors | 1 | 2013 | 10651 | 0.010 |
Why?
|
Insulin | 1 | 2013 | 6686 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2010 | 3235 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 27180 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2018 | 72255 | 0.010 |
Why?
|
Body Weight | 1 | 2007 | 4692 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 5482 | 0.010 |
Why?
|
Age Factors | 1 | 2013 | 18789 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 16011 | 0.010 |
Why?
|